Stay updated with breaking news from Solveigh maehler. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Press release content from Accesswire. The AP news staff was not involved in its creation. CEVEC and CARISMA Therapeutics Sign License Agreement for the Use of CAP(R) Technology in Anti-Tumor Cell Therapies February 2, 2021 GMT CARISMA receives full rights to use the CAP(R) Technology for the production of adenoviral vectors across their whole portfolio of cell therapies for oncology applications CEVEC’s unique CAP(R) cells are specifically designed for highly scalable, RCA-free adenoviral vector manufacturing in suspension bioreactors The agreement supports CARISMA’s development of novel CAR-macrophage immunotherapies, a first-of-its-kind approach to the treatment of solid tumors COLOGNE, GERMANY and PHILADELPHIA, PA / ACCESSWIRE / February 2, 2021 / CEVEC Pharmaceuticals GmbH (CEVEC) and CARISMA Therapeutics Inc. (CARISMA) today announced the signing of an agreement which grants CARISMA a clinical and commercial license for CEVEC’s proprietary CAP(R ....